期刊
JOURNAL OF NUCLEAR MEDICINE
卷 58, 期 9, 页码 1367-1372出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.117.192534
关键词
optical; 3D culture; cancer drug screens; fluorescence imaging; multiphoton microscopy; primary human spheroids
资金
- NCI NIH HHS [R01 CA211082, R01 CA185747, R01 CA205101] Funding Source: Medline
Primary tumor organoids are a robust model of individual human cancers and present a unique platform for patient-specific drug testing. Optical imaging is uniquely suited to assess organoid function and behavior because of its subcellular resolution, penetration depth through the entire organoid, and functional endpoints. Specifically, optical metabolic imaging (OMI) is highly sensitive to drug response in organoids, and OMI in tumor organoids correlates with primary tumor drug response. Therefore, an OMI organoid drug screen could enable accurate testing of drug response for individualized cancer treatment. The objective of this perspective is to introduce OMI and tumor organoids to a general audience in order to foster the adoption of these techniques in diverse clinical and laboratory settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据